EvidenceCare spoke with Venture Nashville Connections on plans to open a $2MM-plus Series A round in the coming months. EvidenceCare plans to use the capital to take the company from beta to wide-scale launch while securing large customers in the healthcare arena. The company has raised $1.5M to date through a small equity Seed Round and Convertible Note rounds A and B. With a beta launch scheduled for the beginning of March, EvidenceCare’s platform currently addresses 12 of the most prevalent decision-making pathways, targeting conditions that account for about 80% of hospital emergency department admissions, including concussion, heart attack, congestive heart failure, sepsis, stroke, seizures, pulmonary embollism (PE), advanced cardiovascular life support (ACLS), COPD/asthma, diabetic emergencies, and pediatric advanced life support (PALS). The company is disrupting the current decision support landscape with a tool that prevents providers from having to absorb “encyclopedic” amounts of content, instead offering a quick, easy to use database curated to be exactly what the provider needs for each specific patient.